Chairman, Dexcom, Inc. Venture Partner, Third Rock Ventures, Former Organizations: Theravance Biopharma,Inc., Five Prime Therapeutics, Cytokinetics
Dr Finer brings 30 years of research and clinical experience including 18 years of experience leading
drug discovery programs, technology development initiatives, preclinical development, and translational
medicine. Prior to joining Third Rock, Dr Finer spent many years in R&D leadership positions at several biotechnology companies. From 2007 to 2011, Dr Finer was Vice President, Discovery at Five Prime Therapeutics, and he served as Director, Drug Discovery Technologies at Cytokinetics after helping launch the company in 1998. Dr Finer has focused his career on breakthrough innovations that have included moving several first-in-class drugs into the clinic and developing novel technology platforms that integrate science, instruments, and informatics. He holds several patents and he has published extensively in peer-reviewed journals. Dr Finer obtained his MD and PhD in Biochemistry from Stanford University School of Medicine, and he holds BS degrees in Chemistry and Biology from Massachusetts Institute of Technology (MIT).